A Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients Switched From EC-MPS.
This study will assess the safety, efficacy and effect on quality of life of switching kidney transplant patients from reduced dose EC-MPS treatment due to gastrointestinal problems to a higher than the equimolar dose of CellCept. Patients will be switched, initially, from EC-MPS (<1440g/day) to an equimolar dose of CellCept, and at the next visit (day 10 +/- 5) the CellCept dose will be increased by 250mg/day, and the daily dose will be split into 3-4 doses. The anticipated time on study treatment is <3 months, and the target sample size is <100 individuals.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||An Open-Label Study to Evaluate the Effect on Quality of Life of Switching Kidney Transplant Patients From Reduced Dose EC-MPS to a Higher Than the Equimolar Dose of CellCept|
- Gastrointestinal Quality of Life index, and Gastrointestinal Symptom Rating Scale, at 3 months.
- Efficacy: Mean dose increase of CellCept. Pharmacokinetics: Comparison of pharmacokinetic parameters under EC-MPS and CellCept therapy. Safety: AEs; acute rejection episodes.
|Study Start Date:||March 2007|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00420472
|Berlin, Germany, 10117|
|Berlin, Germany, 13353|
|Dresden, Germany, 01307|
|Essen, Germany, 45122|
|Hannover, Germany, 30625|
|Köln, Germany, 51109|
|Münster, Germany, 48149|
|Study Director:||Clinical Trials||Hoffmann-La Roche|